Cargando…

Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS)

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group Ltd. 2013
Materias:	Corrections
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898578/ http://dx.doi.org/10.1136/bmj.f4375

Ejemplares similares

Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β(2) agonist: observational matched cohort study (PATHOS)
por: Janson, Christer, et al.
Publicado: (2013)

Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist
por: Yang, Hsi-Hsing, et al.
Publicado: (2017)

Risk of sepsis among patients with COPD treated with fixed combinations of inhaled corticosteroids and long-acting Beta2 agonists
por: Wang, Cheng-Yi, et al.
Publicado: (2019)

Inhaled corticosteroids in COPD and the risk of serious pneumonia
por: Suissa, Samy, et al.
Publicado: (2013)

Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD
por: Lee, Eung Gu, et al.
Publicado: (2023)

Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids
por: Huang, Tsan-Ming, et al.
Publicado: (2020)

Low incidence of pneumonia in COPD patients treated with inhaled corticosteroids undergoing pulmonary rehabilitation
por: Ridolo, Erminia, et al.
Publicado: (2018)

Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD
por: Pavord, Ian D, et al.
Publicado: (2016)

Effect of outpatient therapy with inhaled corticosteroids on decreasing in-hospital mortality from pneumonia in patients with COPD
por: Yamauchi, Yasuhiro, et al.
Publicado: (2016)

Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study
por: Morjaria, Jaymin B., et al.
Publicado: (2017)

Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD
por: Janson, Christer, et al.
Publicado: (2017)

Radiographic Phenotypes Affect the Risk of Inhaled Corticosteroid-Associated Pneumonia in Patients with COPD
por: Lee, Hyo Jin, et al.
Publicado: (2022)

Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial
por: Tashkin, Donald P., et al.
Publicado: (2018)

Inhaled Corticosteroids in Asthma and the Risk of Pneumonia
por: Kim, Min-Hye, et al.
Publicado: (2019)

Estimating Inhaled Corticosteroid Exposure from Short-Acting β(2)-Agonist–Inhaled Corticosteroid Rescue
por: Lugogo, Njira, et al.
Publicado: (2023)

Post-inhaled corticosteroid pulmonary tuberculosis and pneumonia increases lung cancer in patients with COPD
por: Wu, Ming-Fang, et al.
Publicado: (2016)

Outcomes and costs of treating chronic obstructive pulmonary disease with inhaled fixed combinations: the Italian perspective of the PATHOS study
por: Roggeri, Alessandro, et al.
Publicado: (2014)

Risk of pneumonia with inhaled corticosteroid/long-acting β2 agonist therapy in chronic obstructive pulmonary disease: a cluster analysis
por: DiSantostefano, Rachael L, et al.
Publicado: (2014)

Inhaled Corticosteroids Is Not Associated with the Risk of Pneumonia in Asthma
por: Lee, Ye Jin, et al.
Publicado: (2023)

Protective effect of inhaled corticosteroid on children with asthma with Mycoplasma pneumoniae pneumonia
por: Wei, Bing, et al.
Publicado: (2022)

Risk of all-cause mortality or hospitalization for pneumonia associated with inhaled β2-agonists in patients with asthma, COPD or asthma-COPD overlap
por: Amegadzie, Joseph Emil, et al.
Publicado: (2022)

Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β(2)-agonist fixed-dose combination: RE(2)SPOND rationale and study design
por: Rennard, Stephen I, et al.
Publicado: (2016)

Differences in health care outcomes between postdischarge COPD patients treated with inhaled corticosteroid/long-acting β(2)-agonist via dry-powder inhalers and pressurized metered-dose inhalers
por: Wittbrodt, Eric T, et al.
Publicado: (2018)

The association between inhaled corticosteroid and pneumonia in COPD patients: the improvement of patients’ life quality with COPD in Taiwan (IMPACT) study
por: Wang, Cheng-Yi, et al.
Publicado: (2016)

Risk of Pneumonia Associated With the Use of Inhaled Corticosteroids in Asthma
por: Kim, Sang-Heon
Publicado: (2019)

Asthma and treatment with inhaled corticosteroids: associations with hospitalisations with pneumonia
por: Ekbom, Emil, et al.
Publicado: (2019)

Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD
por: Scichilone, Nicola, et al.
Publicado: (2014)

Impact of changes to reimbursement of fixed combinations of inhaled corticosteroids and long-acting β(2)-agonists in obstructive lung diseases: a population-based, observational study
por: Björnsdóttir, U S, et al.
Publicado: (2014)

Correction to: The effect of corticosteroids on the mortality of patients with influenza pneumonia: a systematic review and meta-analysis
por: Ni, Yue-Nan, et al.
Publicado: (2020)

COPD and Osteoporosis: Associated Factors in Patients Treated with Inhaled Corticosteroids
por: Ozcakir, Suheda, et al.
Publicado: (2020)

Corticosteroids for community-acquired pneumonia: time to act!
por: Annane, Djillali, et al.
Publicado: (2008)

Associated Factors of Pneumonia in Individuals with Chronic Obstructive Pulmonary Disease (COPD) Apart from the Use of Inhaled Corticosteroids
por: Lineros, Rosario, et al.
Publicado: (2023)

Comparative efficacy of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD exacerbations: a Bayesian network meta-analysis
por: Oba, Yuji, et al.
Publicado: (2014)

Inhaled Corticosteroids and the Lung Microbiome in COPD
por: Keir, Holly R., et al.
Publicado: (2021)

Blood eosinophilia, use of inhaled corticosteroids, and risk of COPD exacerbations and mortality
por: Oshagbemi, Olorunfemi A., et al.
Publicado: (2018)

Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial
por: Rottenkolber, Marietta, et al.
Publicado: (2015)

Add-on Therapy for Symptomatic Asthma despite Long-Acting Beta-Agonists/Inhaled Corticosteroid
por: Dreher, Michael, et al.
Publicado: (2018)

Inhaled corticosteroids in COPD and onset of type 2 diabetes and osteoporosis: matched cohort study
por: Price, David B., et al.
Publicado: (2019)

Withdrawal of Inhaled Corticosteroids in Patients with COPD – A Prospective Observational Study
por: Nielsen, Anne Orholm, et al.
Publicado: (2021)

Author Correction: The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β(2)-agonists in the United Kingdom: a cross-sectional analysis
por: Pavord, Ian D., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_dkq532od0ukd4k9ce2v3qjacet